RxDoctor Payments DataLook up a doctor →

Damanjit Ghuman, MD

Medical Oncology · Jersey City, NJNPI 1649366832

Payments from drug & device makers

$11,159in general payments, 2019–2025

Across 601 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$929
  • Novartis$886
  • Johnson & Johnson$831
  • Amgen$605
  • E.r. Squibb & Sons, L.L.C.$557
  • Merck$495
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,44494%
  • Education$7166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)53$929
Novartis57$886
Johnson & Johnson(2 entities)45$831
Amgen(2 entities)36$605
E.r. Squibb & Sons, L.L.C.38$557
Merck32$495
Pfizer32$474
Daiichi Sankyo Inc.21$462
Seagen Inc.18$443
Lilly USA, LLC18$320
Sanofi16$300
Astellas Pharma US Inc14$277
Bristol Myers Squibb16$256
Incyte Corporation12$251
Exelixis Inc.6$237
Bayer11$232
Takeda Pharmaceuticals U.S.A., Inc.11$202
Pharmacyclics LLC, An Abbvie Company8$200
Gilead(2 entities)11$199
Genentech USA, Inc.9$169
Eisai Inc.7$149
Puma Biotechnology, Inc.7$138
Boehringer Ingelheim6$134
Regeneron Healthcare Solutions, Inc.8$129
Beigene USA, Inc.9$126
Karyopharm Therapeutics Inc.1$125
Sanofi-aventis U.S. LLC2$115
Sobi, Inc5$114
Pharmaessentia USA Corporation4$107
AbbVie5$100
Array Biopharma Inc5$100
Jazz Pharmaceuticals Inc.5$96
AVEO Pharmaceuticals, Inc.4$95
GSK5$88
GE HealthCare1$75
Stemline Therapeutics Inc.4$68
Tersera Therapeutics LLC2$65
EMD Serono, Inc.4$65
Teva Pharmaceuticals USA, Inc.4$54
Dova Pharmaceuticals3$53
Geron Corporation3$51
Octapharma USA, Inc.2$51
Rigel Pharmaceuticals, Inc.3$46
Azurity Pharmaceuticals, Inc.2$45
Myovant Sciences Inc.3$45
Novocure Inc.2$41
Taiho Oncology, Inc.2$39
Legend Biotech USA Inc.2$36
Blueprint Medicines Corporation2$34
Agios Pharmaceuticals, Inc.2$32
Springworks Therapeutics, Inc.1$30
Tempus AI, Inc1$29
Ipsen Biopharmaceuticals, Inc2$27
Kyowa Kirin, Inc.2$27
Lundbeck LLC1$26
Menarini Silicon Biosystems, Inc.1$25
Corcept Therapeutics1$24
ADC Therapeutics America, Inc.1$21
Myriad Genetic Laboratories, Inc.1$21
Adaptive Biotechnologies Corporation1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,159 in reported general payments places this provider in the 45th percentile of 112 medical oncology providers in New Jersey.

See all medical oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$3,060,690
Medicare patients
801
Services billed
164,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Jersey City

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →